CytomX Therapeutics, Inc. (CTMX)
| Market Cap | 929.56M +1,644.0% |
| Revenue (ttm) | 76.20M -44.8% |
| Net Income | -20.37M |
| EPS | -0.15 |
| Shares Out | 216.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,266,946 |
| Open | 4.320 |
| Previous Close | 4.400 |
| Day's Range | 4.145 - 4.360 |
| 52-Week Range | 0.400 - 8.210 |
| Beta | 2.48 |
| Analysts | Strong Buy |
| Price Target | 12.10 (+181.4%) |
| Earnings Date | May 11, 2026 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclin... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CTMX stock is "Strong Buy." The 12-month stock price target is $12.1, which is an increase of 181.40% from the latest price.
News
Why Is CytomX Therapeutics Stock Falling On Wednesday?
On Tuesday, CytomX Therapeutics announced a public offering of 45.9 million shares at $5.30 per share, pre-funded warrants to purchase 1.179 million shares.
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing...
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it has...
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
The latest data revealed on Monday confirmed response rates in expansion cohorts of 32% at a 10 mg/kg Q3W dose and 20% at an 8.6 mg/kg Q3W dose, with an estimated progression-free survival of 7.1 mont...
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) -
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer
- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - ...
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
CytomX Therapeutics, Inc. (NASDAQ: CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16.
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wi...
CytomX Therapeutics to Present at Upcoming February Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage...
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Wareham Development Leases Full Floor at EmeryStation Research Campus to CytomX Therapeutics
EMERYVILLE, Calif.--(BUSINESS WIRE)--Wareham Development today confirmed a full floor lease has been signed with CytomX Therapeutics at 5959 Horton Street (EmeryStation West).
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to...
CytomX Therapeutics to Present at Upcoming December Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage...
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean M...
CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 s...
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it wil...
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
Leadership team addition to drive strategic long-term value creation and partnering strategy Leadership team addition to drive strategic long-term value creation and partnering strategy
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that manage...
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company's goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active a...
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced...
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean Mc...
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the fir...
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
CytomX Therapeutics, Inc.‘s CTMX share price was up 94.46% at last check on Monday.